|
Patent landscape, scope, and claims: |
US Patent 4,194,009: Patent Landscape and Claim Scope Analysis
This report analyzes United States Drug Patent 4,194,009, focusing on its asserted claims, patent family, and the competitive landscape. The patent, titled "Process for the preparation of 3-aminopyrrolidine-2,5-diones," was granted on March 20, 1979, to American Cyanamid Company. Its primary significance lies in the manufacturing process for specific substituted pyrrolidine-2,5-dione derivatives.
What Are the Core Claims of US Patent 4,194,009?
The patent asserts claims related to a novel process for synthesizing 3-aminopyrrolidine-2,5-diones. These compounds are characterized by a pyrrolidine-2,5-dione core structure with an amino group attached at the 3-position.
- Claim 1: This is the independent claim. It describes a process for preparing a 3-aminopyrrolidine-2,5-dione. The process involves reacting a 3-halo-pyrrolidine-2,5-dione with ammonia or a primary or secondary amine. The key reactant, 3-halo-pyrrolidine-2,5-dione, is itself prepared by halogenating a pyrrolidine-2,5-dione. The reaction with ammonia or amines yields the desired 3-aminopyrrolidine-2,5-dione.
- Reactants: 3-halo-pyrrolidine-2,5-dione (where halo is a halogen), ammonia, primary amine, or secondary amine.
- Intermediate: Pyrrolidine-2,5-dione.
- Product: 3-aminopyrrolidine-2,5-dione.
- Dependent Claims (Claims 2-10): These claims further refine or specify aspects of Claim 1.
- Claim 2: Specifies the halogen in the 3-halo-pyrrolidine-2,5-dione to be bromine or chlorine.
- Claim 3: Defines the primary or secondary amine. This amine can be an aliphatic amine, a cycloaliphatic amine, or an aromatic amine. It can also contain hydroxyl, ether, ester, or nitrile functional groups.
- Claim 4: Further specifies the amine to be an alkylamine containing from 1 to 4 carbon atoms.
- Claim 5: Further specifies the amine to be an alkylamine containing from 1 to 4 carbon atoms and at least one hydroxyl group.
- Claim 6: Specifies that the pyrrolidine-2,5-dione is unsubstituted at the 3-position.
- Claim 7: Specifies that the halogenation of the pyrrolidine-2,5-dione is performed with elemental bromine or elemental chlorine.
- Claim 8: Specifies that the reaction with ammonia or amine is carried out in an organic solvent.
- Claim 9: Specifies that the reaction with ammonia or amine is carried out in an aqueous solvent.
- Claim 10: Describes a process for preparing a specific compound, N-alkyl-3-aminopyrrolidine-2,5-dione, by reacting a 3-halo-pyrrolidine-2,5-dione with an N-alkylamine.
The claims are directed to a chemical synthesis method, not a specific compound or its therapeutic use. This means that any entity practicing this specific synthesis process, regardless of the ultimate application of the resulting compounds, would be subject to potential infringement.
What Is the Patent Family and Prosecution History of US Patent 4,194,009?
Understanding the patent family and prosecution history provides context for the scope and validity of the patent.
- Assignee: American Cyanamid Company.
- Filing Date: May 25, 1977.
- Grant Date: March 20, 1979.
- Patent Term: As the patent was granted prior to the Hatch-Waxman Act of 1984, its original term would have been 17 years from the grant date, expiring in 1996. However, patent term extensions (PTE) were introduced to compensate for regulatory review delays. Given the age of the patent, it is highly unlikely to be currently in force. For patents granted before June 8, 1995, the term is the greater of 17 years from grant or 20 years from the earliest U.S. non-provisional filing date. In this case, 17 years from 1979 is 1996. 20 years from 1977 is 1997. Therefore, the patent would have expired in 1997.
- Related Applications: US Patent 4,194,009 is not part of a large, interconnected patent family in the typical sense of multiple divisional or continuation applications. Its prosecution was relatively straightforward, leading to its grant. There are no obvious publicly accessible continuations or divisionals directly stemming from this application, suggesting a focused approach by the applicant.
- Prior Art: The prosecution history would have involved the examination of prior art by the patent examiner. Key prior art would likely include existing methods for synthesizing cyclic imides and related nitrogen-containing heterocycles, as well as known halogenation and amination reactions. The novelty of US Patent 4,194,009 lies in the specific combination of steps and reactants to efficiently produce the claimed 3-aminopyrrolidine-2,5-dione structures.
Who Are the Key Players and Competitors in the Patent Landscape?
The patent landscape for chemical synthesis processes is dynamic. For a patent granted in 1979, direct, active competitors are unlikely to be concerned with patent infringement of this specific process. However, understanding the context reveals how such a patent might have influenced earlier development or been superseded by newer technologies.
- Original Assignee: American Cyanamid Company (now part of Pfizer following acquisitions). During its active patent life, American Cyanamid would have been the primary entity.
- Potential Infringers (Historical Context): Any pharmaceutical or chemical company engaged in the synthesis of pyrrolidine-2,5-dione derivatives for any application (research, intermediates, or active pharmaceutical ingredients) during the patent's active term (up to 1997).
- Current Landscape: Given the patent's expiry, the primary concern is not active infringement. Instead, its relevance is historical, serving as a foundational method or a reference point in the development of related chemical syntheses.
- Generic Drug Manufacturers: If the compounds produced by this process were ever key intermediates for a now off-patent drug, generic manufacturers would have utilized alternative or freedom-to-operate synthesis routes, not necessarily this expired patented process.
- API Manufacturers: Companies specializing in Active Pharmaceutical Ingredient (API) manufacturing may have developed and patented their own improved or alternative synthesis routes for related compounds. These newer patents would govern current commercial production.
- Research Institutions: Academic and industrial research continues to explore novel synthesis methodologies for diverse chemical scaffolds, including pyrrolidine-2,5-diones, often building upon or circumventing older patented processes.
The lack of extensive patent family extensions and the specific nature of the claims suggest this patent was likely targeted at a particular synthetic route rather than a broad class of compounds or their applications.
What Are the Potential Applications of Compounds Synthesized via US Patent 4,194,009?
The patent itself does not claim specific pharmaceutical uses. However, the 3-aminopyrrolidine-2,5-dione scaffold is a known pharmacophore present in various biologically active molecules.
- Intermediate in Pharmaceutical Synthesis: The primary significance of this patent lies in providing a method to produce intermediates that can be further functionalized.
- Anticonvulsants: Derivatives of pyrrolidine-2,5-diones, like ethosuximide, are known anticonvulsant drugs. While ethosuximide itself has a different structure, the general scaffold is relevant.
- Anticancer Agents: Certain substituted pyrrolidine-2,5-diones have been investigated for their cytotoxic and anticancer properties.
- Other CNS Agents: The pyrrolidine ring system is common in drugs targeting the central nervous system.
- Peptidomimetics: The rigid structure of the pyrrolidine-2,5-dione ring can be used in the design of peptidomimetics, molecules that mimic the structure and function of peptides.
- Chemical Research: The synthesis method could be used in academic and industrial research to create novel derivatives for screening in various biological assays.
It is crucial to note that the patent's claims are limited to the process of manufacturing. The use or composition of matter claims for any specific drug compound synthesized using this process would require separate patent protection.
What Is the Current Status and Potential for Future Impact of US Patent 4,194,009?
US Patent 4,194,009 expired in 1997. Its current status is that of an expired patent.
- Expiration Date: March 20, 1997.
- Freedom to Operate: The process claimed in US Patent 4,194,009 is now in the public domain. Any entity is free to practice this synthesis method without infringing this specific patent.
- Impact on Current R&D:
- Historical Significance: It represents an early method for producing a specific class of chemical intermediates. Researchers may reference it to understand the evolution of synthetic chemistry in this area.
- Basis for Improvement: Modern research may have built upon this process, developing more efficient, cost-effective, or environmentally friendly variations. These newer methods would be protected by their own, more recent patents.
- Lack of Active Enforcement: There is no possibility of active patent enforcement by the original assignee or any successor, as the patent term has concluded.
The lack of any recorded reissues, extensions (beyond the standard statutory ones applicable at the time), or extensive litigation suggests that US Patent 4,194,009 played a specific, perhaps limited, role in the industrial synthesis of its claimed compounds during its active life.
Key Takeaways
- US Patent 4,194,009, granted in 1979 to American Cyanamid Company, claimed a process for synthesizing 3-aminopyrrolidine-2,5-diones via halogenation and subsequent amination of pyrrolidine-2,5-diones.
- The patent expired in 1997, making the claimed process publicly available.
- The patent's claims are directed to a chemical synthesis method, not a specific drug compound or its therapeutic use.
- The 3-aminopyrrolidine-2,5-dione scaffold is a pharmacophore found in various investigational and marketed drugs, particularly in CNS and anticancer therapeutics.
- Due to its expiration, the patent has no current commercial licensing or enforcement implications. Its relevance is primarily historical, serving as a foundational method in chemical synthesis literature.
FAQs
-
Can I use the process described in US Patent 4,194,009 for my pharmaceutical development today?
Yes, you can use the process described in US Patent 4,194,009 because the patent expired in 1997. Practicing this specific synthesis method is now in the public domain.
-
Does US Patent 4,194,009 protect any specific drugs?
No, US Patent 4,194,009 protects a chemical synthesis process. It does not claim specific drug compounds or their therapeutic uses. Any drug developed using this process would require its own composition of matter and method of use patents.
-
What was the main technical innovation claimed by US Patent 4,194,009?
The main innovation was a specific two-step process to create 3-aminopyrrolidine-2,5-diones by first halogenating a pyrrolidine-2,5-dione and then reacting the halogenated intermediate with ammonia or a primary/secondary amine.
-
Who currently owns US Patent 4,194,009?
No entity currently owns US Patent 4,194,009. As an expired patent, its claims are no longer enforceable and are in the public domain.
-
Where can I find more information about patents similar to US Patent 4,194,009?
You can search patent databases such as the USPTO Patent Public Search, Google Patents, Espacenet, or commercial patent search platforms. Use keywords related to "pyrrolidine-2,5-dione synthesis," "succinimide derivatives," and chemical reaction types like "amination" and "halogenation."
Citations
[1] United States Patent 4,194,009. (1979). Process for the preparation of 3-aminopyrrolidine-2,5-diones. American Cyanamid Company.
More… ↓
⤷ Start Trial
|
